59,702 trials (keyword fallback)
Bone Density · Bone Loss · Anorexia Nervosa
Primary: Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) — 0.90; 0.87 g/cm^2 — p=0.009
Fractures, Bone
Primary: Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)…
Primary Hyperparathyroidism · Parathyroid Adenoma · Parathyroid Hyperplasia
Primary: Change in Lumbar Spine Bone Mineral Density — 0.030; 0.042; -0.016 g/cm^2 — p=< 0.00001
Adult Idiopathic Generalized Osteoporosis
Primary: Percent Change in Lumbar Spine Areal BMD by DXA — 5.2 percentage of change
Healthy Volunteer
Primary: Maximum Observed Drug Concentration (Cmax) of Denosumab — 12.7; 11.8 μg/mL
Osteoporosis
Primary: Absolute Difference in the Log-transformed CTX Values Between V4 vs. V6 — 129.15; 71.79; 107.62 log (ng/mL)
Low Bone Mass · Low Bone Mineral Density · Males With Osteoporosis
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — 0.9; 5.7 Percent — p=<0.0001
Bone Metastases in Men With Hormone-Refractory Prostate Cancer · Bone Metastases in Subjects With Advanced Breast Cancer
Primary: Number of Participants With Adverse Events — 98; 45; 28; 22 Participants
Breast Cancer
Primary: Number of Participants With Disease Control Rate at 9 Months — 35 Participants
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
Osteoporosis
Primary: Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion. — -2.1; -4.3; -3.0 percentage change
IOP · Osteoporosis
Primary: Difference in BMD at the Lumbar Spine (L1-4) Within Group — -1.1; -2.4 percentage of change
Trauma · Injuries
Primary: Consumer Assessment of Healthcare Providers and Systems Child Hospital Survey Communication Subscale — 0.769; 0.775; 0.735; 0.747 score on a scale
Cancer · Carcinoma · Castrate-Resistant Prostate Cancer
Primary: Overall Survival Through Month 24 — 174; 184 Participants
Smoldering Multiple Myeloma
Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants